Sign up
Healthed-White-on-Blue
656A1728

Dr Adam Nelson

Interventional Cardiologist and Clinical Trialist; Royal Adelaide Hospital, Queen Elizabeth Hospital, University of Adelaide, Victorian Heart Institute
Dr Adam Nelson is an early career interventional cardiologist and clinical trialist dual-appointed to the Royal Adelaide and Queen Elizabeth Hospitals in addition to the University of Adelaide and the Victorian Heart Institute. Dr Nelson’s academic and clinical interests are in improving adoption of guidelines through implementation science and evaluating emerging therapies for dyslipidaemia, diabetes and obesity.

More from this expert

Glp-1,Related,Drugs,Newspaper,Headlines,With,Hand,And,Magnifying,Glass

Cardiovascular benefits of GLP1s – New evidence

Dr Adam Nelson explains weight loss should now be considered a therapeutic target.

By Dr Adam Nelson
Podcasts iconPodcasts
Blood,Samples,For,Hdl,Cholesterol,(good,Cholesterol),And,Ldl,Cholesterol

Why is LDL control important?

Dr Nelson outlines the evidence behind the latest cholesterol target recommendations.

By Dr Adam Nelson
Podcasts iconPodcasts
Cardiovascular benefits for GLP1s - Novo Nordisk_Smaller

Cardiovascular benefits of GLP-1s – New evidence

Discover how semaglutide 2.4mg aligns with best practice cardiac care guidelines.

By Dr Adam Nelson
Videos iconVideos
Human,Heart,Model,Beside,A,Red,Warning,Sign,With,An

CV medications – Practical strategies to improve compliance

Explore the challenges presented by patient adherence in cardiovascular medicine, and the proven strategies effective in improving adherence rates, including the use of easily-accessible digital tools.

By Dr Adam Nelson
Podcasts iconPodcasts

Discover

Healthed

CPD platform

Upcoming Healthed Webcast

Panel Discussion on The Role of GLP-1 in the Management of CKD in T2D

Tuesday 17th March, 7pm - 9pm AEDT

Speakers

Dr Charlotte Hespe & Dr Ramy Bishay

General Practitioner & Endocrinologist

Join Dr Charlotte Hespe and Dr Ramy Bishay for this expert panel webcast presentation, where they will discuss the role of GLP-1 in the management of CKD in T2D.

Register for webcast